Abstract:Background Doxorubicin (DOX) is a widely utilized anthracycline chemotherapy drug in cancer treatment, yet its efficacy is hindered by both short-term and long-term cardiotoxicity. Although oxidative stress, inflammation and mitochondrial dysfunction are established factors in DOX-induced cardiotoxicity, the precise molecular pathways remain elusive. Further exploration of the pathogenesis and identification of novel molecular targets are imperative. Recent studies have implicated the Sirtuins family in various physiological and pathological processes, suggesting their potential in ameliorating DOX-induced cardiotoxicity. Moreover, research on Sirtuins has discovered small-molecule compounds or medicinal plants with regulatory effects, representing a notable advancement in preventing and treating DOX-induced cardiac injury. Purpose In this review, we delve into the pathogenesis of DOX-induced cardiotoxicity and explore the therapeutic effects of Sirtuins in mitigating this condition, along with the associated molecular mechanisms. Furthermore, we delineate the roles and mechanisms of small-molecule regulators of Sirtuins in the prevention and treatment of DOX-induced cardiotoxicity. Study-design/methods Data for this review were sourced from various scientific databases (such as Web of Science, PubMed and Science Direct) up to March 2024. Search terms included "Sirtuins," "DOX-induced cardiotoxicity," "DOX," "Sirtuins regulators," "histone deacetylation," among others, as well as several combinations thereof. Results Members of the Sirtuins family regulate both the onset and progression of DOX-induced cardiotoxicity through anti-inflammatory, antioxidative stress and anti-apoptotic mechanisms, as well as by maintaining mitochondrial stability. Moreover, natural plant-derived active compounds such as Resveratrol (RES), curcumin, berberine, along with synthetic small-molecule compounds like EX527, modulate the expression and activity of Sirtuins. Conclusion The therapeutic role of the Sirtuins family in mitigating DOX-induced cardiotoxicity represents a potential molecular target. However, further research is urgently needed to elucidate the relevant molecular mechanisms and to assess the safety and biological activity of Sirtuins regulators. This review offers an in-depth understanding of the therapeutic role of the Sirtuins family in mitigating DOX-induced cardiotoxicity, providing a preliminary basis for the clinical application of Sirtuins regulators in this condition.

Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling

SIRT6 activates PPARα to improve doxorubicin-induced myocardial cell aging and damage

Sirt6 Protects Cardiomyocytes Against Doxorubicin-Induced Cardiotoxicity by Inhibiting P53/Fas-dependent Cell Death and Augmenting Endogenous Antioxidant Defense Mechanisms

Deacetylase-independent Function of SIRT6 Couples GATA4 Transcription Factor and Epigenetic Activation Against Cardiomyocyte Apoptosis.

Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury

SIRT1 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the Oxidative Stress and P38mapk Pathways

Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity

Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity

Mitochondrial Sirtuins and Doxorubicin-induced Cardiotoxicity

Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Apoptosis in Mice Through SIRT1-mediated Deacetylation of P53

Cardiac sirtuin1 deficiency exacerbates ferroptosis in doxorubicin-induced cardiac injury through the Nrf2/Keap1 pathway

SIRT4 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the AKT/mTOR/Autophagy Pathway

Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy

Follistatin‐like 1 protects against doxorubicin‐induced cardiotoxicity by preventing mitochondrial dysfunction through the SIRT6/Nrf2 signaling pathway

Breviscapine Remodels Myocardial Glucose and Lipid Metabolism by Regulating Serotonin to Alleviate Doxorubicin-Induced Cardiotoxicity

Doxorubicin-Induced Cardiotoxicity Through SIRT1 Loss Potentiates Overproduction of Exosomes in Cardiomyocytes

Doxorubicin Cardiomyopathy is Ameliorated by Acacetin Via Sirt1-mediated Activation of AMPK/Nrf2 Signal Molecules.

RNA M6a-Regulated Circ-Znf609 Suppression Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating FTO

Dosing Depending on SIRT3 Activity Attenuates Doxorubicin-Induced Cardiotoxicity Via Elevated Tolerance Against Mitochondrial Dysfunction and Oxidative Stress.

Overexpressed SIRT6 Attenuates Cisplatin-Induced Acute Kidney Injury by Inhibiting ERK1/2 Signaling

USP14 modulates cell pyroptosis and ameliorates doxorubicin-induced cardiotoxicity by deubiquitinating and stabilizing SIRT3